Has John Kane received payments from drug or device companies?

Yes. Drug and device makers reported $816,903 in general payments to John Kane across 474 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean John Kane did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about John Kane come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

John Kane

Psychiatry · Glen Oaks, NYNPI 1164556429

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (49.5%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 22.1%. Reporting peaked in 2024 at $191,157 and has fallen 81.0% since, to $36,353 in 2025. Among psychiatry clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$816,903in general payments, 2019–2025

Across 474 payments — averaging $1723.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

H. Lundbeck A S$181K
Teva Pharmaceuticals USA, Inc.$167K
Sumitomo Pharma Co., Ltd.$123K
Alkermes, Inc.$80K
Aurobindo Pharma USA, Inc.$41K
Otsuka Pharmaceutical Development & Commercialization, Inc.$34K
plus $191K from 18 others

$3,161,859in research payments, 2019–2025

Across 10 payments — averaging $316,186 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

E.r. Squibb & Sons, L.L.C.$1.7M
Otsuka Pharmaceutical Development & Commercialization, Inc.$1.4M
H. Lundbeck A S$7K
Teva Pharmaceuticals USA, Inc.$5K

What the payments were for

Consulting fees$404,30149%
Speaking & faculty fees$267,41133%
Travel & lodging$133,21816%
Food & beverage$11,9731%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
H. Lundbeck A S	73	$180,869
Teva Pharmaceuticals USA, Inc.	68	$167,147
Sumitomo Pharma Co., Ltd.	84	$123,426
Alkermes, Inc.	43	$79,811
Aurobindo Pharma USA, Inc.	7	$40,579
Otsuka Pharmaceutical Development & Commercialization, Inc.	24	$34,241
Otsuka Pharmaceutical Co., Ltd.	21	$33,924
E.r. Squibb & Sons, L.L.C.	17	$27,365
Merck	16	$18,611
Otsuka America Pharmaceutical, Inc.	9	$17,744
Johnson & Johnson	7	$15,378
Boehringer Ingelheim	21	$15,232
Indivior Inc.	2	$13,215
Boehringer Ingelheim International GmbH	2	$9,345
Mylan Inc.	41	$9,007
Acadia Pharmaceuticals Inc	11	$8,680
AbbVie	14	$8,136
Neurocrine Biosciences, Inc.	6	$6,326
Sunovion Pharmaceuticals Inc.	1	$4,428
Biogen	2	$1,430
Jazz Pharmaceuticals Inc.	1	$1,400
Microgenics Corporation	1	$500
Lundbeck LLC	2	$72
Janssen Scientific Affairs, LLC	1	$39

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

ABILIFY MAINTENA$201,064
LATUDA$122,727
ARISTADA$95,014
LYBALVI$67,753
Clozapine$48,670
ARISTADA INITIO$21,858
REXULTI$21,647
ABILIFY MYCITE$17,658
AUSTEDO$14,170
INVEGA SUSTENNA$13,488
PERSERIS$13,200
UZEDY$12,707
NUPLAZID$8,518
COBENFY$6,051
INVEGA TRINZA$3,575
MK-8189$2,250
INGREZZA$2,000
INVEGA$1,860
SUNOSI$1,400
Antipsychotic$500

How this compares

$816,903 in reported general payments places this provider in the 95th percentile of 3,713 psychiatry providers in New York.

See all psychiatry providers in New York →

Other psychiatry in Glen Oaks

Christoph CorrellGlen Oaks$1.5M
Youssef HassounGlen Oaks$233K
Jose Rubio-LorenteGlen Oaks$106K
Delbert RobinsonGlen Oaks$83K
Leslie CitromePomona$5.7M
Sanjay GuptaCheektowaga$1.9M
Richard PriceMonsey$1.7M
Adam AshtonAmherst$1.6M
Manish ZinzuvadiaNew York$1.3M
George KruseBronx$1.2M

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →